Home › Myositis › North Carolina
Myositis clinical trials in North Carolina
12 studies for Myositis are looking for participants at sites in North Carolina.
Cities in North Carolina
Environmental Risk Factors for the Anti-synthetase Syndrome
- NIEHS Clinical Research Unit (CRU), Research Triangle Park
RecruitingObservational studyHealthy volunteers welcome
Ages 2 to 100 · All sexes · Updated Sep 28, 2026 · NCT01276470Adult and Juvenile Myositis
- NIEHS Clinical Research Unit (CRU), Research Triangle Park
RecruitingObservational studyHealthy volunteers welcome
Ages 2 to 100 · All sexes · Updated Sep 24, 2026 · NCT00017914RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
- University of North Carolina at Chapel Hill - Accepting Adult Patients, Chapel Hill
- Duke University Medical Center - Accepting Young Adults and Juvenile Patients, Durham
RecruitingPhase 2/3
Ages 6 to 75 · All sexes · Updated Sep 17, 2026 · NCT06154252A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.
- Research Site, Chapel Hill
RecruitingPhase 1
Ages 18 to 70 · All sexes · Updated Sep 15, 2026 · NCT06916806A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
- Atrium Health Rheumatology-Southpark, Charlotte
- Duke University Medical Center, Durham
RecruitingPhase 1
Ages 18 to 74 · All sexes · Updated Sep 10, 2026 · NCT07085104A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
- University of North Carolina TraCS Institute - CTRC, Chapel Hill
RecruitingPhase 1
Ages 18 to 70 · All sexes · Updated Aug 28, 2026 · NCT06925542Descartes-08 in Autoantibody Myositis
- University of North Carolina, Chapel Hill
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 17, 2026 · NCT07391605A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)
- Nkarta Investigational Site, Charlotte
RecruitingPhase 1/2
Ages 18 to 75 · All sexes · Updated Aug 7, 2026 · NCT06733935AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.
- Artiva Investigational Site Charlotte, Charlotte
- Artiva Investigational Site Charlotte, Charlotte
- Artiva Investigational Site Statesville, Statesville
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jul 31, 2026 · NCT06991114A Study of AZD0120 in Autoimmune Diseases
- Research Site, Chapel Hill
RecruitingPhase 1
Ages 18 to 75 · All sexes · Updated Jul 28, 2026 · NCT07295847A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases
- Duke University, Durham
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 14, 2026 · NCT07115745A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease
- Duke University Health System, Durham
RecruitingPhase 1
Ages 12 to 70 · All sexes · Updated May 22, 2026 · NCT06308978From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.